Synovus Financial Corp Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Synovus Financial Corp lifted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 100.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 98,130 shares of the biotechnology company’s stock after buying an additional 49,065 shares during the period. Synovus Financial Corp’s holdings in Precigen were worth $93,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PGEN. Traphagen Investment Advisors LLC acquired a new position in shares of Precigen during the third quarter worth about $29,000. Stifel Financial Corp raised its holdings in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the period. SG Americas Securities LLC lifted its position in Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 25,681 shares during the period. Finally, AQR Capital Management LLC grew its position in Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 18,097 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Precigen Stock Up 2.2 %

Shares of NASDAQ PGEN opened at $0.73 on Friday. Precigen, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $1.93. The business has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $1.15. The firm has a market cap of $212.56 million, a PE ratio of -1.32 and a beta of 1.71.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Precigen in a research note on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.